Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Thyroid disease in pregnancy

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Severe thyrotoxicosis with fever, delirium, heart failure or arrhythmia, or severe hypothyroidism with hypothermia and reduced consciousness, requires emergency maternal resuscitation and senior obstetric-endocrine care. Do not delay treatment because pregnancy complicates drug choice; radioiodine remains contraindicated.

Overview

Interpret pregnancy-specific thyroid physiology, treat maternal hypo- and hyperthyroidism safely, and coordinate fetal, obstetric, postpartum and neonatal follow-up without therapeutic delay.

Maternal thyroid hormone supports pregnancy and fetal neurodevelopment, particularly before the fetal thyroid is fully functional. Both under-treatment and excessive treatment can harm pregnancy, so RCOG recommends care involving clinicians with appropriate obstetric and endocrine experience. Pre-conception optimisation is preferable, but a new diagnosis during pregnancy still requires prompt action.

Physiology changes interpretation. Early hCG stimulation can lower TSH, binding proteins raise total T4, and reference intervals vary by assay and gestation. Hyperemesis-related gestational transient thyrotoxicosis is usually distinguished from Graves' disease by context, goitre or eye signs, antibodies and persistence rather than by one suppressed TSH.

Management includes the fetus and the postpartum period. TSH-receptor antibody concentration, uncontrolled maternal thyrotoxicosis and antithyroid medicines may prompt fetal growth, heart-rate and goitre surveillance. After birth, maternal doses often change rapidly and neonatal clinicians need advance notice when fetal or neonatal thyroid dysfunction is plausible.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Previous Graves pregnancy risk

A pregnant patient previously had radioiodine for Graves' disease and now takes stable levothyroxine with normal TSH. Which additional assessment remains important?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • RCOG Green-top Guideline 76 thyroid disorders in pregnancyCurrent 2025 UK multidisciplinary pregnancy-specific guidance.
  • NICE NG145 thyroid disease recommendationsNational thyroid testing, antithyroid treatment and monitoring framework.
  • BNF carbimazole monographUK prescribing, pregnancy and agranulocytosis safety information.
  • RCOG patient information on thyroid problems in pregnancyPatient-facing explanation of hypothyroidism, hyperthyroidism and postpartum planning.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Key points

  • Pregnancy raises thyroxine-binding globulin and changes total hormone concentrations; interpret TSH and free T4 using gestation- and assay-appropriate reference ranges whenever the laboratory supplies them.
  • Human chorionic gonadotrophin can suppress TSH in early pregnancy. A low TSH alone is not Graves' disease: examine the clinical picture, free hormones, TSH-receptor antibodies and trajectory.
  • Established hypothyroidism usually needs an early levothyroxine increase. The patient should contact the maternity/endocrine team promptly after a positive test rather than wait for routine booking.
  • Levothyroxine is safe and should not be stopped in pregnancy. Separate it from iron, calcium and pregnancy multivitamins because these can reduce absorption.
  • For Graves' hyperthyroidism, use the lowest effective antithyroid medicine exposure that controls maternal disease while avoiding fetal hypothyroidism; drug choice can change across gestation under specialist supervision.
  • Carbimazole is associated with congenital malformations, particularly in the first trimester, while propylthiouracil carries important hepatic toxicity. Pre-conception counselling permits a planned, individualised strategy.

Aetiology

01

Pre-existing autoimmune thyroid disease

Hashimoto or Graves disease may predate conception, with pregnancy changing hormone requirements, antibody activity and maternal or fetal monitoring needs.

02

New pregnancy-associated dysfunction

Gestational transient thyrotoxicosis, postpartum thyroiditis and newly recognised hypothyroidism can emerge through pregnancy-specific immune and hormonal physiology.

03

Treatment-related thyroid imbalance

Inadequate or excessive levothyroxine and antithyroid medicine exposure can affect both maternal physiology and the fetal thyroid.

Pathophysiology

  1. 1
    Pregnancy changes thyroid tests

    Human chorionic gonadotrophin can lower TSH early, while binding proteins raise total hormone and assay-specific gestational ranges alter interpretation.

  2. 2
    Maternal hormone supports the fetus

    Maternal thyroid hormone contributes to pregnancy and early fetal neurodevelopment before fetal thyroid function is fully established.

  3. 3
    Antibodies and medicines cross the placenta

    TSH-receptor antibodies and antithyroid medicines can alter fetal thyroid activity, growth, heart rate and gland size.

  4. 4
    Requirements change after delivery

    Loss of placental physiology and postpartum immune change can rapidly alter maternal replacement or antithyroid needs and reveal thyroiditis.

Clinical features and red flags

Overt maternal hypothyroidism

Raised gestation-adjusted TSH with low free T4 supports overt primary hypothyroidism. Symptoms such as fatigue, constipation and cold intolerance overlap with pregnancy, so biochemical confirmation and timely levothyroxine are essential.

Graves' hyperthyroidismRed flag

Persistent biochemical thyrotoxicosis with goitre, bruit, orbitopathy, prior Graves' disease or positive TSH-receptor antibodies favours Graves' disease over transient hCG-mediated suppression. Maternal tachycardia, weight loss and heart failure indicate severity.

Gestational transient thyrotoxicosis

Early pregnancy, hyperemesis, high hCG states, absent Graves' stigmata and subsequent improvement suggest a transient process. Supportive treatment is often sufficient, but severe dehydration and electrolyte disturbance still need urgent obstetric care.

Fetal thyroid effectRed flag

Persistent fetal tachycardia, growth restriction, fetal goitre, hydrops or abnormal bone maturation can reflect fetal hyper- or hypothyroidism. Maternal antibodies and antithyroid exposure guide specialist interpretation.

Postpartum dysfunction

Postpartum thyroiditis often produces a hyperthyroid phase followed by hypothyroidism; Graves' may also relapse. Pain is unusual, and antibody pattern, Doppler findings and time course help avoid inappropriate antithyroid treatment.

Investigations

  1. 01
    Serum TSH and free T4First step
    Why
    Define maternal thyroid status using pregnancy-appropriate laboratory interpretation.
    Interpretation and limitations
    Use trimester- and assay-specific intervals when available. Repeat after treatment changes at the interval agreed by the maternity/endocrine pathway; do not diagnose overt disease from TSH alone when free hormone and clinical context disagree.
  2. 02
    TSH-receptor antibodies
    Why
    Distinguish autoimmune hyperthyroidism and estimate fetal/neonatal risk in current or previous Graves' disease.
    Interpretation and limitations
    A positive or substantially raised result supports Graves' activity and can cross the placenta. Timing of repeat testing and fetal surveillance follows the specialist obstetric guideline, including after definitive maternal treatment.
  3. 03
    Thyroid peroxidase antibodies
    Why
    Identify autoimmune thyroid disease where this changes risk discussion or treatment thresholds.
    Interpretation and limitations
    Positivity increases future hypothyroidism and postpartum thyroiditis risk but is not itself proof that symptoms require thyroid hormone; interpret alongside TSH, free T4 and pregnancy history.
  4. 04
    Full blood count and liver tests
    Why
    Provide a clinical baseline and investigate antithyroid medicine toxicity when symptoms occur.
    Interpretation and limitations

Differential diagnosis

01

Gestational transient thyrotoxicosis

Hyperemesis, early gestation and absent goitre, eye signs or receptor antibodies favour hCG-related physiology over Graves disease.

02

Graves disease

Persistent hormone excess, goitre, eye disease and TSH-receptor antibodies support autoimmune synthesis and identify fetal surveillance implications.

03

Normal gestational adaptation

A mildly suppressed early TSH with appropriate gestational free-hormone interpretation may be physiological rather than pathological thyrotoxicosis.

04

Postpartum thyroiditis

A painless release phase followed by temporary hypothyroidism after delivery differs mechanistically from recurrent Graves disease.

Management

01HypothyroidismConception to postpartum replacementFirst stepKnown levothyroxine-treated disease, or new raised TSH with biochemical hypothyroidism in pregnancy.+
  1. 1At pregnancy confirmation, contact the endocrine/maternity team promptly and implement the pre-agreed levothyroxine increase or urgent clinician-directed adjustment; check TSH and free T4 without waiting for routine booking.
  2. 2Titrate using pregnancy-specific targets and repeat tests regularly through gestation. Check administration, missed doses and separation from iron or calcium before assuming pharmacological failure.
  3. 3After delivery, reduce toward the pre-pregnancy dose when appropriate and recheck thyroid function around the locally specified postpartum interval; do not abandon follow-up when treatment began only during pregnancy.
02Hyperthyroidism

Complications

01

Miscarriage and hypertensive disease

Poorly controlled maternal hypothyroidism or thyrotoxicosis increases the risks of pregnancy loss, pre-eclampsia and other placental complications.

02

Fetal growth and thyroid dysfunction

Maternal antibodies, uncontrolled hormone excess and treatment exposure can cause fetal growth disturbance, tachycardia, goitre or hypothyroidism.

03

Maternal cardiac decompensation

Severe maternal thyrotoxicosis increases the risk of atrial arrhythmia, heart failure and thyroid storm during infection, labour or surgery.

04

Postpartum relapse or thyroiditis

Rapid immune and treatment changes after birth can destabilise thyroid function when follow-up and dose plans are unclear.

Monitoring and follow-up

  • Document the laboratory's pregnancy reference interval and use the same assay when possible; a non-pregnant range can drive unnecessary dose changes.
  • Recheck TSH and free T4 after levothyroxine or antithyroid adjustment and at planned points through gestation, with frequency increased when control is unstable.
  • In current or previous Graves' disease, schedule TSH-receptor antibody testing and fetal surveillance according to RCOG and the local maternal-medicine pathway.
  • Give written antithyroid medicine toxicity advice and respond the same day to fever, sore throat, mouth ulcers, jaundice or dark urine.
  • Make a delivery and postpartum plan: maternal dose change, timing of repeat tests, breastfeeding-compatible therapy, and neonatal assessment when antibodies or medicines created risk.

Special situations

Past Graves still crosses the placenta

Maternal radioiodine or thyroidectomy removes thyroid output but not necessarily TSH-receptor antibodies. Fetal risk assessment therefore depends on history and antibody testing, not current maternal TSH alone.

TSH lags behind treatment

During hyperthyroidism treatment, TSH may remain suppressed after free hormone improves. Escalating antithyroid medicine solely to normalise TSH can over-treat the fetus.

A fetal goitre has two directions

Maternal stimulating antibodies can cause fetal hyperthyroidism, while excessive antithyroid transfer can cause fetal hypothyroidism. Fetal-medicine assessment is needed before changing maternal treatment.

Postpartum thyroiditis is destructive

Stored hormone leaks during the hyperthyroid phase, so antithyroid medicines usually do not help. Symptom control, phase recognition and later hypothyroid testing are more useful.

Tablets compete in the gut

New pregnancy iron or calcium is a common reason for worsening TSH in a previously stable patient. Timing history may solve the problem without an unnecessarily large replacement increase.

Common pitfalls

  1. 01

    Interpreting a low first-trimester TSH with a non-pregnant reference range and diagnosing Graves' disease automatically.

  2. 02

    Stopping levothyroxine because the patient is pregnant instead of promptly reviewing the higher requirement.

  3. 03

    Using radioiodine imaging or treatment during pregnancy or breastfeeding.

  4. 04

    Titrating antithyroid therapy to TSH alone while free hormone is already controlled.

  5. 05

    Forgetting TSH-receptor antibodies after previous thyroidectomy or radioiodine for Graves' disease.

  6. 06

    Treating the hyperthyroid phase of postpartum thyroiditis as increased hormone synthesis.

  • Radioiodine is contraindicated during pregnancy and breastfeeding. If surgery is essential, timing and preparation are agreed jointly by obstetric, endocrine, anaesthetic and thyroid surgical teams.
  • TSH-receptor antibodies cross the placenta and can affect the fetus even after maternal thyroidectomy or radioiodine. A past Graves' history remains obstetrically relevant.
  • Postpartum immune rebound may trigger Graves' disease or a transient destructive thyroiditis. The hyperthyroid phase of postpartum thyroiditis is not treated with antithyroid medicines because hormone synthesis is not increased.
    • Fever or sore throat requires urgent neutrophil assessment and medicine interruption advice; jaundice, dark urine, pruritus or severe abdominal symptoms require prompt hepatic evaluation, especially with propylthiouracil.
  • 05
    Fetal ultrasound surveillance
    Why
    Assess growth, amniotic fluid, fetal heart rate and thyroid size when maternal disease or treatment creates fetal risk.
    Interpretation and limitations
    A fetal goitre can reflect either stimulation by maternal antibodies or excessive antithyroid exposure. Interpretation and any maternal dose adjustment require fetal-medicine and endocrine input.
  • 06
    Postpartum thyroid function
    Why
    Reassess maternal requirements after delivery and investigate new postpartum symptoms.
    Interpretation and limitations
    Return toward the pre-pregnancy levothyroxine plan when appropriate, then recheck at the guideline-defined interval. A biphasic course suggests thyroiditis; persistent synthesis-driven thyrotoxicosis favours Graves' relapse.
    • Control Graves' disease with minimal fetal exposure
    Overt synthesis-driven thyrotoxicosis rather than isolated low TSH or transient hCG effect.
    +
    1. 1Assess severity, obtain TSH-receptor antibodies and discuss immediately with obstetric-endocrine specialists. Treat thyroid storm or heart failure as a maternal emergency in a monitored setting.
    2. 2Select propylthiouracil versus carbimazole by gestation, prior reaction and individual risk; use the lowest effective dose and avoid block-and-replace during pregnancy unless a highly specialist indication exists.
    3. 3Monitor maternal free hormone and clinical status, arrange fetal surveillance when antibody or treatment risk warrants it, and plan postpartum dose review plus neonatal communication before delivery.
    03Low TSHSeparate physiology from pathologySuppressed TSH detected in early pregnancy, often during hyperemesis assessment.+
    1. 1PreferredCheck free T4 or the locally preferred pregnancy assay, gestational age, symptoms, goitre/eye signs, medication and hCG context rather than labelling Graves' from TSH alone.
    2. 2Support hydration, antiemesis and electrolyte correction for hyperemesis. Request TSH-receptor antibodies and specialist review when Graves' remains plausible or biochemical abnormality is marked or persistent.
    3. 3Repeat thyroid tests to document resolution or evolution. Do not use radioiodine scanning in pregnancy and do not expose transient thyrotoxicosis to unnecessary antithyroid medicine.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    First-line replacement for overt maternal hypothyroidism and selected subclinical disease according to antibody status and obstetric-endocrine guidance.

    Levothyroxine

    Continue the established preparation; increase promptly according to the pre-conception plan or specialist advice, then titrate against gestation-specific tests.

    Take consistently on an empty stomach where feasible and separate from iron, calcium or antacids. Avoid iatrogenic thyrotoxicosis and reassess the dose promptly after delivery.

    Reduces new thyroid hormone synthesis in maternal Graves' disease while avoiding the characteristic carbimazole embryopathy risk in early organogenesis.

    Propylthiouracil

    Specialist-selected lowest effective divided regimen, commonly favoured around conception and the first trimester when an antithyroid medicine is required.

    Serious hepatic injury can occur; provide liver warning symptoms. It crosses the placenta, so excessive treatment can cause fetal hypothyroidism or goitre, and later switching may be considered.

    Controls synthesis-driven maternal hyperthyroidism when benefits outweigh teratogenic and other medicine risks.

    Carbimazole

    Specialist-selected lowest effective dose, with gestation-specific risk discussion and consideration after the first trimester when continuing antithyroid treatment.

    Associated with congenital malformations, especially early in pregnancy. Stop and obtain an urgent blood count for fever, mouth ulcers or sore throat; do not restart after confirmed agranulocytosis.

    Reduces troublesome adrenergic symptoms such as tremor or marked palpitations in selected patients with thyrotoxicosis.

    Propranolol for short symptomatic control

    Use only a short specialist-directed course at the minimum effective dose while definitive control develops; avoid routine prolonged exposure.

    Check asthma, bradycardia and heart failure. Prolonged maternal beta-blockade may affect fetal growth and neonatal heart rate or glucose, so obstetric oversight is required.